1,982 results match your criteria Advances in therapy[Journal]


Adjunctive Agents for Cervical Preparation in Second Trimester Surgical Abortion.

Adv Ther 2019 Apr 19. Epub 2019 Apr 19.

Section of Family Planning, Department of Obstetrics and Gynecology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

Late second trimester dilation and evacuation is a challenging subset of surgical abortion. Among the reasons for this is the degree of cervical dilation required to safely extricate fetal parts. Cervical dilation is traditionally achieved by placing multiple sets of osmotic dilators over two or more days prior to the evacuation procedure; however, there is interest in shortening cervical preparation time. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12325-019-00953-2
Publisher Site
http://dx.doi.org/10.1007/s12325-019-00953-2DOI Listing
April 2019
2 Reads

The Association of Tacrolimus Formulation Switching with Trough Concentration Variability: A Retrospective Cohort Study of Tacrolimus Use Post-Kidney Transplantation Based on National Drug Code (NDC) Numbers.

Adv Ther 2019 Apr 19. Epub 2019 Apr 19.

Formerly Real World Evidence, CTI Clinical Trial and Consulting Services, Raleigh, NC, USA.

Introduction: It was hypothesized that patients experiencing at least one tacrolimus formulation switch may require more frequent therapeutic drug monitoring, subsequent dose adjustments, and a potential for untoward clinical outcomes than patients who remain on a single formulation.

Methods: Eligible patients were adult kidney transplant recipients with stable renal function at month 3 post-transplant and no evidence of acute rejection, receiving an oral, tacrolimus-based regimen. Patients were categorized into two groups (fixed or variable formulation) using the US National Drug Code (NDC) on the basis of tacrolimus formulation usage over the 12-month period. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-019-00950-5DOI Listing
April 2019
1 Read

Study Protocol for a Prospective, Multicenter, Randomized, Open-Label, Parallel-Group Clinical Trial Comparing the Efficacy and Safety of a Needle-Free Insulin Injector and a Conventional Insulin Pen in Controlling Blood Glucose Concentrations in Chinese Patients with Type 2 Diabetes Mellitus (The FREE Study).

Adv Ther 2019 Apr 19. Epub 2019 Apr 19.

Department of Endocrinology, The First Affiliated Hospital of China Medical University, Shenyang, China.

Introduction: China has the largest number of diabetic patients in the world. In the past 2 decades, the prevalence of diabetes in China has increased dramatically, and the current status of diabetes control in the diabetic population is not satisfactory. Although insulin is currently recognized in diabetes treatment guidelines as the therapeutic option for patients not adequately controlled by diet/exercise and oral agents, the proportion of patients with type 2 diabetes using insulin is still very low, and the time when insulin therapy is initiated is relatively late. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-019-00951-4DOI Listing

Economic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs.

Adv Ther 2019 Apr 19. Epub 2019 Apr 19.

University of Nebraska Medical Center, Omaha, NE, USA.

Introduction: Assess the cost-effectiveness (US healthcare payer perspective) of sarilumab subcutaneous (SC) 200 mg + methotrexate versus conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) or targeted DMARD + methotrexate for moderate-to-severe rheumatoid arthritis (RA) in adults with inadequate response to methotrexate.

Methods: Microsimulation based on patient profiles from MOBILITY (NCT01061736) was conducted via a 6-month decision tree and lifetime Markov model with 6-monthly cycles. Treatment response at 6 months was informed by a network meta-analysis and based on American College of Rheumatology (ACR) response. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12325-019-00946-1
Publisher Site
http://dx.doi.org/10.1007/s12325-019-00946-1DOI Listing
April 2019
1 Read

Anti-MEK and Anti-EGFR mAbs in RAS-Mutant Metastatic Colorectal Cancer: Case Series and Rationale.

Adv Ther 2019 Apr 12. Epub 2019 Apr 12.

Platform of Transfer in Cancer Biology, Centre Georges-François Leclerc, 21000, Dijon, France.

KRAS (Kirsten rat sarcoma viral oncogene) or BRAF (v-raf murine sarcoma viral oncogene homolog B1) constitutive activation leads to anti-EGFR (epidermal growth factor receptor) therapy resistance of metastatic colorectal cancer patients. In this article we investigate the effects of anti-MEK (mitogen-activated protein kinase) antibody (trametinib) combined with anti-EGFR (cetuximab) on colon cancer cell lines with different RAS statuses. Even though cetuximab has no effect on RAS cell viability and ERK (extracellular-signal-regulated kinase) phosphorylation (one of the last kinases of the EGFR pathway), trametinib can induce cell death and inhibit the activation of ERK alone or in combination with cetuximab. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12325-019-00949-y
Publisher Site
http://dx.doi.org/10.1007/s12325-019-00949-yDOI Listing
April 2019
5 Reads

Correction to: A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA.

Adv Ther 2019 Apr 12. Epub 2019 Apr 12.

Ossian Health Economics and Communications GmbH, Basel, Switzerland.

The article "A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA", written by Pierre Johansen, Barnaby Hunt, Neeraj N. Iyer, Tam Dang-Tan, Richard F. Pollock was originally published electronically on the publisher's internet portal (currently SpringerLink) on November 27, 2018 without Open Access. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-019-00945-2DOI Listing

Gender Effects in the Efficacy of Racemic Amphetamine Sulfate in Children with Attention-Deficit/Hyperactivity Disorder.

Adv Ther 2019 Apr 10. Epub 2019 Apr 10.

Meridien Research, Bradenton, FL, USA.

Introduction: A laboratory classroom study in children aged 6-12 years with attention-deficit/hyperactivity disorder (ADHD) found that racemic amphetamine sulfate (RA-AMPH) significantly improved performance versus placebo from 45 min through 10 h post-dose (NCT01986062). A secondary analysis assessed gender as a potential moderator of response to treatment comparing the ADHD Rating Scale-IV (ADHD-RS-IV) and Swanson, Kotkin, Agler, M-Flynn and Pelham (SKAMP) rating scales.

Methods: After 8 weeks of open-label RA-AMPH dose optimization using improvement in ADHD-RS-IV symptoms as a guide, 97 subjects (38 females and 59 males) were randomized to the sequence of 2 weeks of double-blind treatment with the optimized dose of RA-AMPH followed by placebo or vice versa during a laboratory classroom day. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-019-00942-5DOI Listing
April 2019
1 Read

Comparison of Doppler-Guided Transanal Hemorrhoidal Dearterialization for Grade III and IV Hemorrhoids in Vietnam.

Adv Ther 2019 Apr 10. Epub 2019 Apr 10.

Hanoi Medical University, Hanoi, Vietnam.

Introduction: This study aimed to assess the short- and long-term outcomes of Doppler-guided transanal hemorrhoidal dearterialization (THD) for grade III and IV hemorrhoidal disease in Vietnam.

Methods: In a prospective observational design, patients treated for grade III and IV hemorrhoidal disease with the THD method at the National Hospital of Traditional Medicine (Hanoi, Vietnam) were included between June 2012 and December 2013. Patients were evaluated postoperatively at the time they were discharged from the hospital (short-term outcome) and 6 months after surgery (long-term outcome). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-019-00948-zDOI Listing
April 2019
2 Reads

Efficacy of Triamcinolone Acetonide Extended-Release in Participants with Unilateral Knee Osteoarthritis: A Post Hoc Analysis.

Adv Ther 2019 Apr 9. Epub 2019 Apr 9.

Flexion Therapeutics, Inc, 10 Mall Road, Suite 301, Burlington, MA, 01803, USA.

Introduction: Osteoarthritis (OA) is common and its prevalence is increased in military service members. In a phase 3 randomized controlled trial (NCT02357459), a single intra-articular injection of an extended-release formulation of triamcinolone acetonide (TA-ER) in participants with unilateral or bilateral knee OA demonstrated substantial improvement in pain and symptoms. Bilateral knee pain has emerged as a confounding factor in clinical trials when evaluating the effect of a single intra-articular injection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-019-00944-3DOI Listing
April 2019
5 Reads

Indirect Comparison of Ropinirole and Pramipexole as Levodopa Adjunctive Therapy in Advanced Parkinson's Disease: A Systematic Review and Network Meta-Analysis.

Adv Ther 2019 Apr 8. Epub 2019 Apr 8.

GlaxoSmithKline, Collegeville, PA, USA.

Introduction: To evaluate the comparative efficacy and safety of ropinirole and pramipexole as adjunctive therapies to levodopa (L-dopa) for the management of advanced Parkinson's disease (PD), via a systematic review and network meta-analysis.

Methods: Twenty-one double-blind randomised controlled trials of patients with advanced PD with motor fluctuations receiving L-dopa comparing ropinirole or pramipexole with comparators were identified from 2550 publications. Bayesian indirect comparison methods were applied to independently review efficacy outcomes including off-time reduction, Unified Parkinson's Disease Rating Scale-Activity of Daily Living (UPDRS-ADL) and UPDRS-motor scores, and safety outcomes including adverse events (AE) and patient withdrawals, to determine indirect treatment comparison mean differences (MD) or hazard ratios (HR) with 95% confidence intervals (CI). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-019-00938-1DOI Listing
April 2019
1 Read

Outcomes Associated with Treatment of Chronic Pain with Tapentadol Compared with Morphine and Oxycodone: A UK Primary Care Observational Study.

Adv Ther 2019 Apr 8. Epub 2019 Apr 8.

Grünenthal Ltd, Stokenchurch, UK.

Introduction: This study compared adverse outcomes and resource use for patients with a diagnosis of pain treated with tapentadol prolonged-release (PR) versus those treated with morphine controlled-release (CR) and oxycodone CR.

Methods: Data were sourced from the Clinical Practice Research Datalink (CPRD), a database derived from UK primary care. Patients prescribed tapentadol PR between May 2011 and December 2016 were selected and matched to two groups of controls treated with either morphine CR or oxycodone CR on gender, age, pain duration, pain site, pain aetiology, Charlson index and prior analgesia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-019-00932-7DOI Listing

Observational Prospective Study to Determine the Evolution of the Symptomatic Profile of Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients and Its Relation to the Control of the Disease.

Adv Ther 2019 Apr 8. Epub 2019 Apr 8.

Hospital Universitario de Canarias, La Laguna, Spain.

Objective: To evaluate the evolution of disease-related symptoms and its relationship with the control of the disease in first-line treatment in patients with metastatic non-small cell lung cancer (NSCLC).

Methods: This was an observational, prospective, national and multicentre study with two visits in which the following were collected: (1) baseline visit: sociodemographic and clinical variables (2) visit after completing the 4-6 chemotherapy cycles: criteria for ending treatment, control of the disease and clinical variables. Ad hoc questionnaires were collected to assess the frequency of symptoms (evaluated by the patient), and quality-of-life questionnaires to assess the intensity of symptoms (using the Lung Cancer Symptom Scale, LCSS), and interference in the patient's daily life, assessed by the patient and by the investigator. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-019-00931-8DOI Listing
April 2019
1 Read

Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial.

Adv Ther 2019 Apr 5. Epub 2019 Apr 5.

Japan-Asia Data Science, Astellas Pharma Inc., Tokyo, Japan.

Introduction: This study evaluated efficacy and safety/tolerability of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in Japanese anemic non-dialysis-dependent chronic kidney disease (NDD-CKD) patients.

Methods: In this phase 2, double-blind, 24-week study, NDD-CKD patients were randomized to oral placebo or roxadustat (50, 70, or 100 mg) three times weekly (TIW) for 6 weeks followed by dose adjustments to maintain hemoglobin (Hb) at 10-12 g/dL for 18 weeks; patients meeting pre-defined criteria were re-randomized to TIW or once-weekly dosing. The primary end point was rate of rise of Hb (g/dL/week) during the first 6 weeks; secondary end points included response rate (Hb ≥ 10. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-019-00943-4DOI Listing
April 2019
1 Read

Metastatic Renal Cell Cancer: An Analysis of Reimbursement Decisions.

Adv Ther 2019 Apr 5. Epub 2019 Apr 5.

Eisai Co. Ltd., Woodcliff Lake, NJ, USA.

Introduction: Metastatic renal cell carcinoma is a complex cancer for which several drugs have been developed over the years. More recently, drugs that target the specific cancer cell mutations have been developed for metastatic cell carcinoma. However, even with the recent influx of targeted therapy options, significant unmet needs exist in around half of treated renal cell carcinoma patients following the failure of first-line therapy. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12325-019-00947-0
Publisher Site
http://dx.doi.org/10.1007/s12325-019-00947-0DOI Listing
April 2019
2 Reads

Prevalence and Control of Dyslipidemia in Patients Referred for High Blood Pressure: The Disregarded "Double-Trouble" Lipid Profile in Overweight/Obese.

Adv Ther 2019 Apr 5. Epub 2019 Apr 5.

Internal Medicine and Geriatrics, "Hypertension Excellence Centre" of the European Society of Hypertension (ESH), "LIPIGEN Centre" of the Italian Society for the Study of Atherosclerosis (SISA), IRCCS-INRCA, Ancona, Italy.

Introduction: We evaluated the prevalence and control of dyslipidemia in a wide sample of patients referred to our ESH "Hypertension Excellence Centre" for high blood pressure (BP). Furthermore, we evaluated the role of adiposity on the serum lipid profile.

Methods: Observational study on 1219 consecutive outpatients with valid ambulatory BP monitoring (ABPM) referred for high BP. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-019-00941-6DOI Listing

A 48-Week, Multicenter, Open-Label, Observational Study Evaluating Oral Rivastigmine in Patients with Mild-to-Moderate Alzheimer's Disease in Taiwan.

Adv Ther 2019 Apr 5. Epub 2019 Apr 5.

Department of Neurology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.

Introduction: Rivastigmine is a cholinesterase inhibitor, approved for the treatment of mild-to-moderate dementia of Alzheimer's type. This study assessed the short- and long-term effectiveness and safety of rivastigmine in patients with mild-to-moderate Alzheimer's disease (AD) in a real-world clinical setting in Taiwan.

Methods: This was a 48-week, single-arm, open-label, prospective, observational, post-marketing surveillance, multicenter study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-019-00939-0DOI Listing
April 2019
3 Reads

Real-World Study of Once-Daily, Extended-Release Tacrolimus Versus Twice-Daily, Immediate-Release Tacrolimus in Kidney Transplantation: Clinical Outcomes and Healthcare Resource Utilization.

Adv Ther 2019 Apr 2. Epub 2019 Apr 2.

Northwestern University Transplant Outcomes Research Collaborative (NUTORC), Comprehensive Transplant Center, Northwestern University, 676 N. St. Clair Street, 19th Floor, Chicago, IL, 60611, USA.

Introduction: Real-world data with extended-release tacrolimus (ER-T) are lacking in the USA. This study examined clinical outcomes and healthcare resource utilization in kidney transplant patients receiving ER-T in clinical practice.

Methods: This was a retrospective, single-center analysis (February-June 2016) using data from Northwestern University's Enterprise Data Warehouse. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-019-00904-xDOI Listing
April 2019
3 Reads

Integrating Osimertinib in Clinical Practice for Non-Small Cell Lung Cancer Treatment.

Adv Ther 2019 Apr 2. Epub 2019 Apr 2.

Medical Oncology, Cytecare Hospital, Bengaluru, India.

Treatment of non-small cell lung cancer (NSCLC) is evolving with the use of precision medicine for patients with sensitizing epidermal growth factor receptor (EGFR) mutation. First- and second-generation EGFR tyrosine kinase inhibitors (TKIs) remained the standard of care for patients with EGFR-mutated advanced NSCLC for about a decade. However, treatment resistance eventually develops for most patients who experience initial response to these agents. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-019-00917-6DOI Listing
April 2019
1 Read

A Multicenter, Observational, Prospective Study of the Effectiveness of Switching from Budesonide/Formoterol Turbuhaler to Budesonide/Formoterol Easyhaler.

Adv Ther 2019 Apr 2. Epub 2019 Apr 2.

Orion Corporation, Orion Pharma, Espoo, Finland.

Introduction: In real-life practice, asthma remains poorly controlled, with a considerable burden on patients' quality of life. Budesonide/formoterol (B/F) Easyhaler has demonstrated similar dose consistency, therapeutic equivalence, and equivalent bronchodilator efficacy to B/F Turbuhaler, but no real-life comparisons are yet available in patients switching from B/F Turbuhaler to B/F Easyhaler.

Methods: The primary objective of this real-life, non-interventional, observational study was to show non-inferiority of asthma control when adult patients in Swedish primary care with persistent asthma switched from B/F Turbuhaler to B/F Easyhaler. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-019-00940-7DOI Listing
April 2019
1 Read

Differentiating Basal Insulin Preparations: Understanding How They Work Explains Why They Are Different.

Adv Ther 2019 Mar 30. Epub 2019 Mar 30.

The Ohio State University Wexner Medical Center, Columbus, OH, USA.

Since the introduction of insulin as a life-saving agent for patients with type 1 diabetes, insulin preparations have evolved to approximate physiologic insulin delivery profiles to meet prandial and basal insulin needs. While prandial insulins are designed to have quick time-action profiles that minimize postprandial glucose excursions, basal insulins are designed to have a protracted time-action profile to facilitate basal glucose control over 24 h. Given that all insulins have the same mechanism of action at the target tissue level, the differences in time-action profiles are achieved through different mechanisms of protraction, resulting in different behaviors in the subcutaneous space and different rates of absorption into the circulation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-019-00925-6DOI Listing
March 2019
4 Reads

Economic Burden of Illness Among Commercially Insured Patients with Systemic Sclerosis with Interstitial Lung Disease in the USA: A Claims Data Analysis.

Adv Ther 2019 Mar 30. Epub 2019 Mar 30.

University of Colorado School of Medicine, Denver, CO, USA.

Introduction: Interstitial lung disease (ILD) is a common manifestation of scleroderma/systemic sclerosis (SSc). However, the direct and indirect economic burdens of SSc-ILD remain unclear. This study assessed and compared healthcare resource utilization (HRU), direct healthcare costs, work loss, and indirect costs between patients with SSc-ILD and matched controls with neither SSc nor ILD in the USA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-019-00929-2DOI Listing
March 2019
5 Reads

Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China.

Adv Ther 2019 Mar 21. Epub 2019 Mar 21.

School of Pharmaceutical Sciences, Peking University, Beijing, China.

Introduction: To assess the cost-effectiveness of alectinib versus crizotinib as first-line treatments for advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) patients from the perspective of China's healthcare system.

Methods: A Markov model was developed to assess the clinical outcomes and costs of alectinib and crizotinib, which included five health states: progression-free (PF) without central nervous system (CNS) progression, PF with CNS progression, post-progression (PP) without CNS progression, PP with CNS progression, and death. Clinical data for transition probabilities were obtained from the ALEX trial at the updated data cutoff. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-019-00908-7DOI Listing

A Propensity Score Matched Comparison of Brand and Biosimilar Basal Insulin in Non-Critical Hospitalized Patients with Type 2 Diabetes Mellitus.

Adv Ther 2019 Mar 21. Epub 2019 Mar 21.

Qingdao Endocrine and Diabetes Hospital, Fuzhou Road 81, Qingdao, 266071, China.

Introduction: Comparisons between brand and biosimilar basal insulin in hospitalized patients are lacking. We aimed to compare the efficacy and safety of brand insulin glargine vs. biosimilar insulin glargine in non-critical hospitalized patients with type 2 diabetes mellitus (T2DM). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-019-00922-9DOI Listing
March 2019
6 Reads
2.438 Impact Factor

The Effectiveness, Safety, and Tolerability of Pirfenidone in Idiopathic Pulmonary Fibrosis: A Retrospective Study.

Adv Ther 2019 Mar 21. Epub 2019 Mar 21.

Department of Chest Diseases, Dokuz Eylül University, İzmir, Turkey.

Introduction: In this study we aimed to investigate the effectiveness and safety profile of pirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF) in a real-life setting.

Methods: Clinical records of patients diagnosed with mild-to-moderate IPF and receiving pirfenidone treatment across three centers in Turkey between January and September 2017 were retrospectively collected. Pulmonary function measurements, including percentage of forced vital capacity (FVC%) and percentage of diffusion capacity (DLCO%) were analyzed in patients who received pirfenidone treatment for at least 6 months. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12325-019-00928-3
Publisher Site
http://dx.doi.org/10.1007/s12325-019-00928-3DOI Listing
March 2019
4 Reads
2.438 Impact Factor

Appropriate Titration of Basal Insulin in Type 2 Diabetes and the Potential Role of the Pharmacist.

Adv Ther 2019 Mar 21. Epub 2019 Mar 21.

Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, CO, USA.

A substantial proportion of patients with suboptimal control of their type 2 diabetes experience delays in treatment intensification. Additionally, patients often experience overuse of basal insulin, commonly referred to as "over-basalization," whereby basal insulin continues to be uptitrated in order to meet targets, when addition of a mealtime bolus insulin dose may be a more appropriate option. In order to overcome these challenges, there is a need to develop the capacity of allied healthcare professionals to provide appropriate support to these patients, such as during initiation or titration of basal insulin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-019-00907-8DOI Listing

Correction to: Cerebrolysin for the Treatment of Aneurysmal Subarachnoid Hemorrhage in Adults: A Retrospective Chart Review.

Adv Ther 2019 Mar 21. Epub 2019 Mar 21.

Department of Neurosurgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.

Unfortunately the funding information is incorrect in the published article. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-019-00930-9DOI Listing
March 2019
1 Read

The Effectiveness of Ankaferd Blood Stopper in the Management of Traumatic Bleeding.

Authors:
Nazmiye Koyuncu

Adv Ther 2019 Mar 21. Epub 2019 Mar 21.

Department of Emergency Medicine, Haydarpaşa Numune Education and Research Hospital, Istanbul, Turkey.

Introduction: The objective of this study was to prospectively compare the effectiveness of Ankaferd Blood Stopper (ABS) with dry sponges in cessation of bleeding in adult trauma cases with external bleeding due to extremity lacerations.

Methods: The study was conducted on patients with bleeding associated with extremity lacerations. All consecutive patients presented to the emergency department of a high-volume training hospital in Istanbul were recruited within the study period. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12325-019-00935-4
Publisher Site
http://dx.doi.org/10.1007/s12325-019-00935-4DOI Listing
March 2019
5 Reads

Pharmacological Treatment for Non-alcoholic Fatty Liver Disease.

Adv Ther 2019 Mar 19. Epub 2019 Mar 19.

Department of Gastroenterology and Hepatology, Antwerp University Hospital, Antwerp, Belgium.

Non-alcoholic fatty liver disease (NAFLD) has become the most frequently encountered chronic liver disease. NAFLD is associated with increased liver-related morbidity and mortality, but also contributes to cardiovascular disease, diabetes and non-liver-related malignancy. Non-alcoholic steatohepatitis (NASH) is considered the more severe subtype of NAFLD that drives most of these adverse outcomes. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12325-019-00898-6
Publisher Site
http://dx.doi.org/10.1007/s12325-019-00898-6DOI Listing
March 2019
5 Reads

Switching "Real-World" Diabetes Patients to Degludec from Other Basal Insulins Provides Different Clinical Benefits According to Their Baseline Glycemic Control.

Adv Ther 2019 Mar 16. Epub 2019 Mar 16.

eSwiss Medical and Surgical Center, St Gallen, Switzerland.

Introduction: The stable, ultra-long duration of action of insulin degludec (degludec) minimizes fluctuations in glucose-lowering activity over the daily (24-h) dosing period, and comparative studies with other basal insulins suggest that these properties translate into a lower risk of hypoglycemia at equivalent levels of glycemic control. Results from the real-world European multicenter, retrospective chart review study of 2550 patients with type 1 and type 2 diabetes (T1D and T2D) in routine clinical care EU-TREAT (NCT02662114) showed that patients benefited from improved glycemic control and significantly reduced rates of hypoglycemia following a switch to degludec.

Methods: In this post hoc analysis, EU-TREAT patients were stratified into good (≤ 7. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-019-00916-7DOI Listing
March 2019
3 Reads

Assessing the Role of Anti rh-GAA in Modulating Response to ERT in a Late-Onset Pompe Disease Cohort from the Italian GSDII Study Group.

Adv Ther 2019 Mar 16. Epub 2019 Mar 16.

Department of Clinical and Experimental Medicine, UOC di Neurologia e Malattie Neuromuscolari, University of Messina, Messina, Italy.

Introduction: Patients with late-onset Pompe disease (LOPD) receiving enzyme replacement therapy (ERT) may develop IgG antibodies against alglucosidase alpha (anti-rhGAA) in the first 3 months of treatment. The exact role of these antibodies in modulating efficacy of ERT in this group of patients is still not fully understood. To assess whether anti rh-GAA antibodies interfere with ERT efficacy, we studied a large Italian cohort of LOPD patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-019-00926-5DOI Listing
March 2019
1 Read

Thyroid Cancer Benefits the Prognosis of Ovarian Cancer: A SEER-Based Study.

Adv Ther 2019 Mar 16. Epub 2019 Mar 16.

Department of General Surgery, Zhejiang Provincial People's Hospital, Hangzhou Medical College, Hangzhou, China.

Introduction: To explore the effect of a second thyroid cancer (TC) on ovarian cancer (OC) patient survival, we compared OC patients with or without a second primary TC using data from the Surveillance, Epidemiology, and End Results (SEER) database.

Methods: Data for OC only, female TC only and OC patients with a second TC (OC2TC) from two periods, 2000-2014 and 1980-1994, were extracted from the SEER database. Differences in clinicopathological and treatment characteristics were analysed using the chi-square test. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12325-019-00918-5
Publisher Site
http://dx.doi.org/10.1007/s12325-019-00918-5DOI Listing
March 2019
9 Reads

Efficacy of Chondroitin Sulfate in Patients with Knee Osteoarthritis: A Comprehensive Meta-Analysis Exploring Inconsistencies in Randomized, Placebo-Controlled Trials.

Adv Ther 2019 Mar 16. Epub 2019 Mar 16.

Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium.

Introduction: There are some controversies about treatment modalities in osteoarthritis (OA), including chondroitin sulfate (CS). The objective of this study was to determine whether CS is effective at alleviating pain and improving function in patients with knee OA and to identify the factors that explain inconsistencies in clinical trial results.

Methods: We conducted a systematic review of randomized, placebo-controlled trials, searching the databases Medline, Cochrane central register for controlled trials and Scopus. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-019-00921-wDOI Listing

Bloating and Abdominal Distension: Clinical Approach and Management.

Adv Ther 2019 Mar 16. Epub 2019 Mar 16.

Division of Gastroenterology, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel.

Functional abdominal bloating and distension (FABD) are common gastrointestinal complaints, encountered on a daily basis by gastroenterologists and healthcare providers. Functional abdominal bloating is a subjective sensation that is commonly associated with an objective abdominal distension. FABD may be diagnosed as a single entity (the sole or cardinal complaint) or may overlap with other functional gastrointestinal disorders such as functional constipation, irritable bowel syndrome, and functional dyspepsia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-019-00924-7DOI Listing

Maximum Tolerated Dose and Pharmacokinetics of Paclitaxel Micellar in Patients with Recurrent Malignant Solid Tumours: A Dose-Escalation Study.

Adv Ther 2019 Mar 16. Epub 2019 Mar 16.

Department of Oncology, Lund University Hospital, Skåne University Hospital, 221 85, Lund, Sweden.

Introduction: A water-soluble Cremophor EL-free formulation of paclitaxel, in which retinoic acid derivates solubilize paclitaxel by forming micelles (paclitaxel micellar), was studied for the first time in man to establish the maximum tolerated dose (MTD) and to characterize the pharmacokinetics (PK).

Methods: This was an open-label, one-arm, dose-escalating study in patients with advanced solid malignant tumours, for which no standard therapy was available or had failed. Paclitaxel micellar was given as 1-h intravenous infusion every 21 days for 3 cycles, mainly without premedication. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-019-00909-6DOI Listing
March 2019
4 Reads

The Case for the Use of Patient and Caregiver Perception of Change Assessments in Rare Disease Clinical Trials: A Methodologic Overview.

Adv Ther 2019 Mar 16. Epub 2019 Mar 16.

Casimir, Plymouth, MA, USA.

Introduction: The traditional model of evaluating treatments based primarily on primary outcome measures has stumbled in its application to rare disease. Rare disease clinical trials face the methodological challenges of small, heterogeneous patient populations and relatively few validated, disease-specific outcome measures. Incorporating qualitative research into rare disease clinical trials may help sponsors, regulators, payers, and prescribers to better understand the real-world and patient-specific impact of a potential therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-019-00920-xDOI Listing

Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1.

Adv Ther 2019 Mar 16. Epub 2019 Mar 16.

AveXis, Inc., Bannockburn, IL, USA.

Introduction: Infants with spinal muscular atrophy (SMA) type 1 typically face a decline in motor function and a severely shortened life expectancy. Clinical trials for SMA type 1 therapies, onasemnogene abeparvovec (AVXS-101) and nusinersen, demonstrated meaningful improvements in efficacy (e.g. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-019-00923-8DOI Listing
March 2019
1 Read

Long-Term Effects and Adverse Events of Nintedanib Therapy in Idiopathic Pulmonary Fibrosis Patients with Functionally Advanced Disease.

Adv Ther 2019 Mar 14. Epub 2019 Mar 14.

Department of Pulmonology, Semmelweis University, Budapest, Hungary.

Introduction: Idiopathic pulmonary fibrosis (IPF) is one of the most common interstitial lung diseases with limited survival. The effect of IPF therapy in patients with severely impaired lung function is not well established. The aim of this study was to characterize IPF patients with a forced vital capacity (FVC) < 50% (group 1) and FVC 50-60% predicted (group 2) and analyze the effect and adverse events of nintedanib in Hungarian patients diagnosed between April 2015 and July 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-019-00906-9DOI Listing
March 2019
5 Reads

A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA.

Adv Ther 2019 Mar 14. Epub 2019 Mar 14.

Ossian Health Economics and Communications GmbH, Basel, Switzerland.

Introduction: The SUSTAIN 3 and 7 clinical trials compared the efficacy and safety of once-weekly semaglutide relative to exenatide extended-release (ER) and dulaglutide, respectively, in the treatment of patients with type 2 diabetes (T2D). The trials included a series of clinically relevant single and composite endpoints focused on improving glycemic control and reducing body weight, while avoiding hypoglycemia. The present study combined SUSTAIN 3 and 7 outcomes with short-term treatment costs to evaluate the relative cost of control of once-weekly semaglutide versus exenatide ER and dulaglutide. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12325-019-00915-8
Publisher Site
http://dx.doi.org/10.1007/s12325-019-00915-8DOI Listing
March 2019
5 Reads

Correction to: Safety and Efficacy of Ripasudil in Japanese Patients with Glaucoma or Ocular Hypertension: 3-month Interim Analysis of ROCK-J, a Post-Marketing Surveillance Study.

Adv Ther 2019 Mar 13. Epub 2019 Mar 13.

Post Marketing Surveillance Department, Kowa Company, Ltd., Tokyo, Japan.

In the original publication values in the results section are incorrect. Errors were also identified in Fig. 5. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-019-0892-4DOI Listing
March 2019
4 Reads

Biomarkers in Non-Small Cell Lung Cancers: Indian Consensus Guidelines for Molecular Testing.

Adv Ther 2019 Apr 12;36(4):766-785. Epub 2019 Mar 12.

Department of Medical and Hemato-oncology, Cancer Institute, Medanta - The Medicity, Gurugram, Haryana, India.

Novel molecular targets and promising targeted therapies have reshaped diagnostics in patients with advanced non-small cell lung cancer (NSCLC). Despite this progress, the implementation of molecular screening to identify predictive biomarkers in Indian clinical and pathology settings has been challenging due to operational and logistical constraints. This consensus guideline brings together medical oncologists, molecular pathologists and pathologists from India to provide a quick and competent reference for biomarker testing in NSCLC. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12325-019-00903-y
Publisher Site
http://dx.doi.org/10.1007/s12325-019-00903-yDOI Listing
April 2019
10 Reads

Indirect Treatment Comparison of the Efficacy and Safety of Sarilumab Monotherapy in Rheumatoid Arthritis Patients with Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs.

Adv Ther 2019 Apr 12;36(4):817-827. Epub 2019 Mar 12.

Sanofi France, Chilly-Mazarin, France.

Introduction: To evaluate the comparative efficacy and safety of subcutaneous sarilumab 200 mg monotherapy administered every 2 weeks (q2w) versus other monotherapies of biologic, targeted and conventional synthetic disease-modifying antirheumatic drugs (bDMARDs, tsDMARDs, csDMARDs) at recommended doses for treatment of rheumatoid arthritis in patients who are intolerant of or inadequate responders to csDMARDs (csDMARD-IR).

Methods: A systematic literature review and network meta-analysis (NMA) were conducted on 24-week efficacy outcomes: Health Assessment Questionnaire Disability Index (HAQ-DI) score, American College of Rheumatology (ACR) 20/50/70 criteria, and European League Against Rheumatism Disease Activity Score 28-joint count erythrocyte sedimentation rate (DAS28) < 2.6. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-019-00912-xDOI Listing
April 2019
2 Reads

A Critical Overview of the Biological Effects of Mitomycin C Application on the Cornea Following Refractive Surgery.

Adv Ther 2019 Apr 11;36(4):786-797. Epub 2019 Mar 11.

Clínica Novovisión, Madrid, Spain.

During the last 2 decades, modifying the shape of the cornea by means of laser photoablation has emerged as a successful and popular treatment option for refractive errors. Corneal surface ablation techniques such as photorefractive keratectomy (PRK) and laser-assisted subepithelial keratomileusis (LASEK) offer good refractive results while having a minimal impact on corneal biomechanical stability. Past limitations of these techniques included the long-term regression of refractive outcome and a vigorous healing response that reduced corneal clarity in some patients (giving rise to what is clinically described as "haze"). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-019-00905-wDOI Listing

Accurate Estrogen Receptor Quantification in Patients with Negative and Low-Positive Estrogen-Receptor-Expressing Breast Tumors: Sub-Analyses of Data from Two Clinical Studies.

Adv Ther 2019 Apr 11;36(4):828-841. Epub 2019 Mar 11.

White Plains Hospital, White Plains, NY, USA.

Introduction: Accurate assessment of estrogen receptor (ER) expression is crucial to ensure that patients with early breast cancer are accurately identified for appropriate treatment with endocrine therapy. Reverse transcriptase polymerase chain reaction (RT-PCR), compared with immunohistochemistry (IHC), may provide a more precise indication of ER status. Data were pooled and analyzed from two independent, but similarly designed, studies that examined ER status by IHC and the 21-gene Recurrence Score that employs RT-PCR-based methodology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-019-0896-0DOI Listing
April 2019
2 Reads

The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes in Asia.

Authors:
Ju-Ming Lu

Adv Ther 2019 Apr 11;36(4):798-805. Epub 2019 Mar 11.

Department of Endocrinology, Chinese PLA General Hospital, Beijing, China.

The improvement of glycemic control in patients with type 2 diabetes (T2D) is an urgent need in Asia. East Asian T2D patients have distinct characteristics, including relatively low body weight, early impairment of islet beta cell function with reduced insulin secretion and a marked increase in postprandial blood glucose levels. Control of postprandial hyperglycemia and beta cell preservation are key elements of the therapeutic strategy for these patients. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12325-019-00914-9
Publisher Site
http://dx.doi.org/10.1007/s12325-019-00914-9DOI Listing
April 2019
6 Reads

Patient Needs, Perceptions, and Attitudinal Drivers Associated with Obesity: A Qualitative Online Bulletin Board Study.

Adv Ther 2019 Apr 11;36(4):842-857. Epub 2019 Mar 11.

Novartis Pharma AG, Basel, Switzerland.

Introduction: To gain insights into the needs, attitudes, perceptions, and preferences of people living with obesity using an online bulletin board (OBB) study.

Methods: The OBB is a moderated asynchronous online qualitative market research method that allows interactive discussion among participants. Participants were recruited via physician referral followed by screening questions to ensure eligibility and willingness to participate. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-019-00900-1DOI Listing

Factors Associated with the Initiation of Long-Acting Injectable Paliperidone Palmitate Versus Aripiprazole Among Medicaid Patients with Schizophrenia: An Observational Study.

Adv Ther 2019 Apr 8;36(4):858-869. Epub 2019 Mar 8.

Janssen Scientific Affairs, LLC, Titusville, NJ, USA.

Introduction: Factors underlying the selection of antipsychotics for patients with schizophrenia are poorly understood. This study investigated variables associated with initiation of treatment with the long-acting injectables paliperidone palmitate (LAI-PP) and aripiprazole LAI (LAI-AP) in Medicaid patients with schizophrenia.

Methods: Adults with at least one medical or pharmacy claim for LAI-PP or LAI-AP from 1 January 2013 to 31 December 2016 were selected from the IBM MarketScan Medicaid Database. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-019-00913-wDOI Listing
April 2019
3 Reads